
Systemic cytokine potential in patients with chronic obstructive pulmonary disease who completed treatment for pulmonary tuberculosis
Author(s) -
А. А. Хренов,
Viktoriya Sergeevna Fedoseeva,
М М. Гришин
Publication year - 2020
Publication title -
tuberkulez i bolezni lëgkih/tuberkulëz i bolezni lëgkih
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.226
H-Index - 12
eISSN - 2542-1506
pISSN - 2075-1230
DOI - 10.21292/2075-1230-2020-98-1-22-26
Subject(s) - medicine , copd , tuberculosis , cytokine , lung , systemic inflammation , tumor necrosis factor alpha , gastroenterology , immunology , inflammation , pathology
The objective : to investigate the cytokine potential (TGF-β1, TNF-α, IL-1β, IL-4) in the systemic blood circulation of patients who successfully completed treatment for pulmonary tuberculosis, depending on whether they have chronic obstructive lung disease (COPD). Subjects and methods . The study included 118 patients who had successfully completed treatment for pulmonary tuberculosis by the time of the examination. Group 1 included 79 patients with different forms of pulmonary tuberculosis without COPD, Group 2 – 39 patients with different forms of pulmonary tuberculosis and concurrent COPD. The Control Group consisted of 24 healthy individuals.In all patients, the levels of IL-1β, TNF-α and IL-4, as well as the active form of TGF-β1 were tested in the systemic blood circulation using commercial ELISA test systems. Results . By the time of successful tuberculosis treatment completion, COPD patients were found to develop the following: a special Th2-associated form of immune imbalance characterized by the reduced systemic level of TNF-α in combination with the increased level of IL-4; the increased risk of development and progression of pulmonary fibrosis due to the high level of growth factor TGF-β1 (in comparison with patients without COPD); elevated levels of TGF-β1 (compared with patients without COPD), creating favorable endogenous conditions for tuberculosis relapse.